Encouraging survival rates in patients with acute myocardial infarction treated with an intra-aortic balloon pump by Valk, S.D.A. (Suzanne) et al.
ORIGINAL ARTICLE
Encouraging survival rates in patients
with acute myocardial infarction treated
with an intra-aortic balloon pump
S. D. A. Valk & J. M. Cheng & C. A. den Uil &
W. K. Lagrand & M. van der Ent & M. van de Sande &
R. T. van Domburg & M. L. Simoons
Published online: 18 January 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Objective To evaluate a 30-day and long-term outcome of
patients with acute myocardial infarction (AMI) treated
with intra-aortic balloon pump (IABP) counterpulsation and
to identify predictors of a 30-day and long-term all-cause
mortality.
Methods Retrospective cohort study of 437 consecutive
AMI patients treated with IABP between January 1990 and
June 2004. A Cox proportional hazards model was used to
identify predictors of a 30-day and long-term all-cause
mortality.
Results Mean age of the study population was 61±11 years,
80% of the patients were male, and 68% had cardiogenic
shock. Survival until IABP removal after successful
haemodynamic stabilisation was 78% (n=341). Cumulative
30-day survival was 68%. Median follow-up was 2.9 years
(range, 6 months to 15 years). In patients who survived
until IABP removal, cumulative 1-, 5-, and 10-year survival
was 75%, 61%, and 39%, respectively. Independent
predictors of higher long-term mortality were prior cere-
brovascular accident (hazard ratio (HR), 1.8; 95% confi-
dence interval (CI), 1.0–3.4), need for antiarrhythmic drugs
(HR, 2.3; 95% CI, 1.5–3.3), and need for renal replacement
therapy (HR, 2.3; 95% CI, 1.2–4.3). Independent predictors
of lower long-term mortality were primary percutaneous
coronary intervention (PCI; HR, 0.6; 95% CI, 0.4–1.0), failed
thrombolysis with rescue PCI (HR, 0.5; 95%CI, 0.3–0.9), and
coronary artery bypass grafting (HR, 0.3; 95% CI, 0.1–0.5).
Conclusions Despite high in-hospital mortality in patients
with AMI treated with IABP, a favourable number of
patients survived in the long-term. These results underscore
the value of aggressive haemodynamic support of patients
throughout the acute phase of AMI.
Keywords Acute myocardial infarction . Intra-aortic
balloon pump . Outcome . Predictors . Survival
Introduction
The intra-aortic balloon pump (IABP) was introduced by
Kantrowitz et al. in 1968 as a means of circulatory support
in haemodynamically unstable patients in cardiogenic
shock following acute myocardial infarction (AMI) [1]. In
the years thereafter, indications for its use have expanded.
Today, it is used mainly as a mechanical support device in
addition to pharmacological treatment in patients with low
cardiac output or sustained myocardial ischaemia. In
patients with AMI, IABP reduces afterload, which leads
to a more effective and easier emptying of the left ventricle
which will increase cardiac output. It may also reduce
myocardial ischaemia by augmenting coronary perfusion
[2, 3].
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The IABP may improve cardiac performance and
haemodynamic parameters while the ischaemic myocardi-
um recovers. IABP also decreases the incidence of
recurrent ischaemia and infarct-related artery re-occlusion
after reperfusion therapy, improves survival when used in
conjunction with thrombolytic therapy compared with
thrombolytic therapy alone, and enhances rescue percuta-
neous coronary intervention (PCI) for failed thrombolysis.
Other indications for IABP use are mechanical complica-
tions of AMI, refractory ventricular arrhythmias, support
during high-risk PCI and preoperative support for high-risk
cardiac surgery [4–8].
Despite increasing experience, more frequent utilisation
and broadening indications for IABP use, little is known
about the long-term outcome after IABP treatment of AMI.
This study was conducted to investigate the in-hospital and
long-term outcome of patients with AMI treated with IABP,
and to identify predictors of in-hospital and long-term
survival.
Methods
Patient Selection
We conducted a single-centre retrospective follow-up study.
All 437 consecutive patients admitted with AMI and treated
with IABP between January 1990 and June 2004 were
included. Data were acquired from patient records and local
databases. Indications for IABP use were AMI with
cardiogenic shock, haemodynamic support during PCI,
refractory or post-myocardial infarction angina, valvular
dysfunction, mechanical complication, or refractory ven-
tricular arrhythmia after AMI.
Balloon Pump
From 1990 to 1995, Datascope 9.5 and 10.5 French
catheters were used. Between 1995 and 2000, 9-French
Arrow catheters were used. From 2000 until the end of
2004, 8-French Arrow catheters were used.
Study Definitions
Cardiogenic shock was defined as systolic blood pressure
≤90 mmHg due to impaired cardiac function diagnosed
by echocardiography and associated with clinical signs of
decreased cardiac output not responsive to optimalisation
of filling pressures. Relevant complications were limb
ischaemia requiring IABP removal, bleeding, embolic
and thrombotic events, need for vascular surgery, and
infection. Limb ischaemia was defined as diminished or
absent peripheral pulsations. Bleeding complications
were classified as major and minor. Major bleeding was
defined as bleeding requiring red cell transfusion, minor
bleeding as any access site bleeding. IABP-related
infection was defined as fever with an increase in white
blood cell count, C-reactive protein (>5 mg/l), and signs
of local infection. Blood and catheter tip cultures to
confirm the diagnosis of IABP-related infection were not
available. Left ventricular systolic function (LVF) was
estimated qualitatively by echocardiography. LVF was
classified as normal, moderate, impaired, or severely
depressed.
Follow-up
Follow-up for vital status was obtained by contacting the
civil registry and was complete in 99.5% at the reference
date of December 2004. For two patients who moved
abroad, the latest available information was used. Minimal
follow-up duration was 6 months.
Statistical Analysis
Discrete variables were compared with the χ2 or Fisher’s
exact test when appropriate and are presented as percen-
tages. Continuous variables were compared with the
Student’s t test and are presented as mean±standard
deviation. Survival data were analysed using the Kaplan–
Meier method. Survival curves were compared with the
log-rank test. Univariate and multivariate Cox proportion-
al hazard regression analyses were performed to delineate
predictors of in-hospital and long-term survival. Prese-
lected variables were age, gender, blood pressure and
heart rate, diabetes, hypertension, smoking, hypercholes-
terolaemia, positive family history, peripheral vascular
disease, prior cerebrovascular accident (CVA), AMI,
PCI, coronary artery bypass grafting (CABG), infarct
location, extent of vessel disease, LVF, treatment during
IABP use, cardiopulmonary resuscitation (CPR), and
IABP running time.
Results
Baseline Characteristics
The baseline characteristics of the study population are
presented in Table 1. The mean age of the population was
61±11 years. Eighty per cent of the patients were male.
The median follow-up was 2.9 years (range, 6 months to
15 years). Indications for IABP use were cardiogenic
shock (68%), haemodynamic support during PCI (6%),
high-risk CABG (17%), refractory or post-myocardial
infarction angina (9%), valvular dysfunction or mechanical
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complications (8%), or refractory ventricular arrhythmias
(1%). In some patients there was more than one
indication for IABP support. Reperfusion therapy was
performed in 84%. Forty per cent of the patients were
treated with primary PCI, 25% with thrombolysis, 21%
had a rescue PCI and 25% were treated with emergency
CABG.
Predictors of Successful IABP Weaning
Baseline characteristics of patients who survived until
IABP removal (78%, n=341) are presented in Table 2.
IABP running time in this group was 1 day in 23%,
2–5 days in 57%, and ≥6 or more days in 20% of these
patients. Patients with IABP running time≥6 days had a
significantly lower systolic blood pressure and were more
often in cardiogenic shock. Prior AMI, prior CABG,
diminished LVF, administration of inotropic or antiarrhyth-
mic drugs (AAD) and need for resuscitation were also
significantly more frequent in this subgroup as compared
with an IABP running time of 2–5 days. They were also
less frequently treated with primary PCI.
Thirty-Day and Long-term Outcome
Cumulative survival was 58%, 47%, and 30% at 1, 5, and
10 years follow-up, respectively. In the patient group who
survived until IABP removal, cumulative survival was
75%, 61%, and 39% at 1, 5, and 10 years follow-up,
respectively. Patients with IABP running time of ≥6 days
had a significantly higher long-term mortality compared
with patients with an IABP running time of 2–5 days
(p<0.05) (Fig. 1).
Adjusted predictors of 30-day mortality are presented in
Table 3. Age (hazard ratio (HR) 1.03; 95% CI, 1.0–1.06),
cardiogenic shock (HR, 2.7; 95% CI, 1.2–6.0), the need for
inotropic agents (HR, 7.5; 95% CI, 2.8–19.6) and CPR
(HR, 2.3; 95% CI, 1.2–4.2) were independently associated
with lower 30-day survival. Independent predictors of
higher 30-day survival were treatment with primary PCI
(HR, 0.2; 95% CI, 0.1–0.5), thrombolysis (HR, 0.1; 95%
CI, 0.0–0.8), rescue PCI (HR, 0.3; 95% CI, 0.1–0.6), and
CABG (HR, 0.1; 95% CI, 0.0–0.3).
Adjusted predictors of long-term mortality in patients
who survived until IABP removal are presented in Table 3.
Prior CVA or transient ischaemic attack (TIA; HR, 1.8;
95% CI, 1.0–3.4), need for AAD (HR, 2.3; 95% CI, 1.5–
3.3), and renal replacement therapy (HR, 2.3; 95% CI, 1.2–
4.3) were independently associated with lower long-term
survival. Independent predictors of higher long-term sur-
vival were primary PCI (HR, 0.6; 95% CI, 0.4–1.0), rescue
PCI (HR, 0.5; 95% CI, 0.3–0.9), and CABG (HR, 0.3; 95%
CI, 0.1–0.5).
Table 1 Baseline and clinical characteristics of patients with AMI
treated with IABP
Total (n=437)
Age (years) 61±11
Male gender (%) 80
Risk factors (%)
Diabetes 20
Hypertension 36
Smoking 51
Hypercholesterolaemia 30
Peripheral vascular disease 10
History (%)
CVA/TIA 8
AMI 50
CABG 10
PCI 11
Systolic blood pressure (mmHg) 108±28
Diastolic blood pressure (mmHg) 65±17
Heart rate (bpm) 94±25
Left ventricular function (%)
Normal/moderate 19
Impaired 24
Severely depressed 25
Unknown 32
Three vessel/left main stem coronary disease (%) 44
Cardiogenic shock (%) 68
Infarct location (%)
Antero-septal wall 64
Infero-posterior wall 36
Reperfusion therapy (%) 84
Primary PCI 40
Thrombolysis 25
Rescue PCI 21
CABG 25
No reperfusion therapy 16
Treatment during ICCU stay (%)
Inotropic agents 72
Cardiopulmonary resuscitation 25
Mechanical ventilation 54
Antiarrhythmic drugs 43
Renal replacement therapy 4
IABP running time (%)
1 day 31
2 to 5 days 51
≥6 days 18
Data are presented as mean±SD, or as a percentage
AMI acute myocardial infarction, IABP intra-aortic balloon pump, SD
standard deviation, CVA cerebrovascular accident, TIA transient
ischaemic attack, CABG coronary artery bypass grafting, PCI
percutaneous coronary intervention, mmHg millimetres of mercury,
bpm beats per minute, ICCU intensive cardiac care unit
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IABP Use Over the Years
Between 1990 and 1994 (period I) 116 patients were treated
with IABP: from 1995 to 1999 (period II) 141 patients and
between 2000 and 2004 (period III) 180 patients. Mean age
was 62±9, 59±12, 63±11 years in period I, II and III
respectively (p<0.05). No difference in the number of
patients in cardiogenic shock was observed. The use of
primary PCI increased from 20% in period I to 58% in
period III (p<0.001). The use of thrombolytic therapy
(p<0.01) and emergency CABG (p<0.01) decreased. The
utilisation of reperfusion therapy increased over time
Table 2 Baseline and clinical characteristics of patients with AMI who survived until IABP removal, stratified by IABP running time
Total (n=341) 1 day (n=77) 2–5 days (n=195) ≥6 days (n=69) p value
Age (years) 61±11 63±11 60±11 60±11 0.1
Male gender (%) 80 79 78 84 0.5
Risk factors (%)
Diabetes 21 20 22 17 0.7
Hypertension 37 46 38 26 0.1
Smoking 51 46 50 60 0.3
Hypercholesterolaemia 32 36 31 29 0.6
Peripheral vascular disease 10 15 9 7 0.2
History (%)
CVA/TIA 8 8 9 7 0.9
AMI 50 60 44 57 <0.05
CABG 10 14 6 16 <0.05
PCI 13 18 12 9 0.2
Systolic blood pressure (mmHg) 110±28 119±25 110±30 103±26 <0.01
Diastolic blood pressure (mmHg) 67±17 71±16 66±17 63±16 <0.05
Heart rate (bpm) 92±25 87±25 91±26 97±22 0.1
Left ventricular function (%) <0.001
Normal/moderate 22 29 21 17
Impaired 28 23 30 29
Severely depressed 24 9 25 39
Unknown 26 39 24 15
Three vessel/left main stem coronary disease (%) 43 45 42 46 0.4
Cardiogenic shock (%) 61 48 63 71 <0.05
Infarct location (%) 0.4
Antero-septal wall 63 60 66 54
Infero-posterior wall 37 40 34 46
Reperfusion therapy (%)
Primary PCI 41 51 43 25 <0.01
Thrombolysis 26 19 26 34 0.1
Rescue PCI 21 13 21 30 0.1
CABG 30 35 28 31 0.5
No reperfusion therapy 11 5 9 22 <0.01
Treatment during ICCU stay (%)
Inotropic agents 68 43 72 86 <0.001
Cardiopulmonary resuscitation 19 13 17 30 <0.05
Mechanical ventilation 50 46 52 52 0.6
Antiarrhythmic drugs 45 26 44 70 <0.001
Renal replacement therapy 4 0 5 7 0.1
Data are presented as mean±SD, or as a percentage
AMI acute myocardial infarction, IABP intra-aortic balloon pump, SD standard deviation, CVA cerebrovascular accident, TIA transient ischaemic
attack, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, mmHg millimetres of mercury, bpm beats per minute,
ICCU intensive cardiac care unit
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(p<0.01). Mean IABP running time decreased from three to
two days between period I and III. The complication rate
decreased from 28% to 9% (p<0.001) Thirty-day mortality
decreased from 41% to 26% (p<0.05).
IABP-Related Complications
Complications were observed in 88 patients (20%). The
most frequently observed complications were infection
(n=34; 8%), bleeding (n=23; 5%), and limb ischaemia
(n=21; 5%). Of all bleeds, five patients had major
bleeding. Limb ischaemia was transient in the majority
of the cases (n=17, 81%), with either spontaneous
recovery, or after IABP removal. Vascular surgery was
needed in four patients (19%).
Discussion
The main finding of this study is that the use of the IABP in
patients admitted with AMI is associated with an excellent
prognosis in hospital survivors. Almost half of these
patients are alive after 10-year follow-up. In-hospital
mortality declined over the years and was lower in patients
in whom IABP support was required for a relatively short
period (5 days or less).
In this study in-hospital survival was 68%. Other studies
have reported survival rates ranging from 71% to 79%. This
observation, however, must be seen in perspective to the
percentage of patients in cardiogenic shock in our popula-
tion (68% compared with 19–27% in other studies) [9–12].
Mortality rates for AMI and cardiogenic shock are as high
as 60% [13]. The relatively high survival rate despite a high
percentage of cardiogenic shock may be due to the higher
use of reperfusion therapy (84%) in our study compared
with other studies [7]. The incidence of cardiogenic shock
has only slightly declined over the years but in-hospital
survival increased due to increased use of reperfusion
therapy [14–16]. A recent report by our group on a
subgroup of patients from this present study also underlines
Fig. 1 Long-term survival according to IABP running time
HR 95% CI
Predictors of 30-day mortality in patients with AMI treated with IABP
Age 1.03 1.0–1.06
Cardiogenic shock 2.7 1.2–6.0
Reperfusion therapy
Primary PCI 0.2 0.1–0.5
Thrombolysis 0.1 0.0–0.8
Rescue PCI 0.3 0.1–0.6
CABG 0.1 0.0–0.3
Inotropic agents 7.5 2.8–19.6
Resuscitation 2.3 1.2–4.2
Predictors of long-term mortality in patients with AMI who survived until IABP removal
CVA/TIA 1.8 1.0–3.4
Reperfusion therapy
Primary PCI 0.6 0.4–1.0
Rescue PCI 0.5 0.3–0.9
CABG 0.3 0.1–0.5
Antiarrhythmic drugs 2.3 1.5–3.3
Renal replacement therapy 2.3 1.2–4.3
Table 3 Multivariate regression
analysis
Only statistically significant
predictors are described
IABP intra-aortic balloon pump,
AMI acute myocardial
infarction, HR hazard ratio, CI
confidence interval, CABG
coronary artery bypass grafting,
PCI percutaneous coronary
intervention, CVA
cerebrovascular accident, TIA
transient ischaemic attack
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the usefulness of IABP support in conjunction with
reperfusion therapy leading to encouraging 30-day and
long-term survival rates in patients with AMI complicated
by cardiogenic shock [17].
Predictors of lower in-hospital survival were advanced
age, diminished LVF, longer IABP running time, the need
for inotropic support and resuscitation. CABG or PCI were
associated with higher in-hospital survival. This is in line
with the findings of Stone et al., who also found that
increased age and cardiogenic shock were associated with
worse in-hospital survival and that coronary revascularisa-
tion was a strong independent predictor of in-hospital
survival [9].
To our knowledge, this is the first study reporting up to
15 years of follow-up of patients admitted with AMI and
treated with IABP. Our results show that although initial in-
hospital mortality is relatively high, when discharged from
the hospital alive, long-term survival was better than
expected. Almost 50% of these patients are still alive after
10 years follow-up. As a large proportion of our population
was in cardiogenic shock at presentation, survival is
certainly better than expected.
Predictors of long-term mortality were previous CVA/
TIA, the need for AAD and renal replacement therapy.
These probably represent patients in a worse clinical
condition requiring additional supportive therapy. However,
PCI or CABG were associated with sustained long-term
survival benefit in a study by Van Domburg et al. [18]. This
shows that the beneficial effect of reperfusion therapy
extends beyond the acute moment [14].
Despite older age, a decline in in-hospital mortality was
observed over the years which seems to be related to
expanding treatment options and the increasing use of
reperfusion therapy. In the latest inclusion period almost
60% underwent primary PCI. This increase in primary PCI is
reflected in the decrease in emergency CABG. Nowadays
even more patients admitted with AMI undergo primary PCI.
In-hospital mortality was highest on the first day after
IABP insertion. This group mainly consisted of patients
who could not be stabilised. Early IABP removal was
possible in patients who had the IABP inserted during PCI
for transient hypotension or because of a large myocardial
area at risk. From days 2 to 5 in-hospital mortality was
relatively low. This group represented patients who could
be stabilised. IABP running time of ≥6 days was associated
with increased in-hospital mortality. These patients survive
the first days after admission but either remain unstable or
develop complications eventually leading to death.
The most frequent complications were limb ischaemia,
bleeding from the IABP entry site and infection. Previously
reported complication rates range from 7% to 47% [19–23].
The Benchmark registry reported a complication rate of
8.1% which is lower than observed in this study. Our
complication rate may be higher due to our study
definitions. Ischaemia was present when patient records
mentioned diminished or absent pulsations. Detection of
diminished pulsations may be subjective and may poten-
tially lead to a higher ischaemia percentage. Infection was
more prevalent (8%) than in the Benchmark registry. This
may also be caused by our less strict definition of IABP-
related infection as no definite tip or blood cultures were
available to confirm the diagnosis. However, a study by
Cristal et al. reported true bacteraemia and sepsis in IABP
patients in 15% and 12%, respectively, mainly during the
first 48 h after insertion [24]. As shown in previous studies,
complication rate decreased with the introduction of smaller
French size catheters [22, 25, 26].
Limitations
Since Erasmus MC is a tertiary referral centre, selection bias
may influence our results. However, this probably leads to an
underestimation of the effect as our study population consists
of high-risk patients. Due to incomplete documentation of
several clinical variables, information bias cannot be excluded.
Conclusions
This is, to our knowledge, the first study reporting on
15 years of follow-up in patients with AMI treated with
IABP. Almost half of the in-hospital survivors are still alive
after 10 years of follow-up, which is better than expected.
Furthermore, in-hospital mortality was related to IABP
running time, with the highest mortality during the first day
(patients in severe cardiogenic shock who could not be
stabilised), a decrease in mortality from days 2 to 5 and from
day 6 on again a higher mortality (patients with severe
impairment who did not recover). Finally, a trend towards
lower in-hospital mortality was observed over the years. So,
despite older age and a trend towards more cardiogenic shock,
survival is quite good, and aggressive haemodynamic support
is useful even up to 5 days after IABP insertion.
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